Dialyse aktuell, Inhaltsverzeichnis Dialyse aktuell 2012; 16(07): 418-419DOI: 10.1055/s-0032-1328817 Forum der Industrie Georg Thieme Verlag KG Stuttgart · New YorkIMPACT-SHPT-Studie – Paricalcitol ermöglicht effizientere Therapie des sekundären Hyperparathyreoidismus Artikel empfehlen Abstract Volltext Referenzen Literatur 1 Kalantar-Zadeh K et al. Kidney Int 2006; 70: 771-780 2 Naves-Díaz M et al. Nephrol Dial Transplant 2011; 26: 1938-1947 3 Floege J et al. Nephrol Dial Transplant 2011; 26: 1948-1955 4 Rodriguez M et al. Am J Physiol Renal Physiol 2005; 288: F253-F264 5 Joy MS et al. J Manag Care Pharm 2007; 13: 397-411 6 Martin KJ, Gonzalez EA. J Am Soc Nephrol 2007; 18: 875-885 7 Kovesdy CP, Kalantar-Zadeh K. K. Kidney Int 2008; 73: 1355-1363 8 Teng M et al. J Am Soc Nephrol 2005; 16: 1115-1125 9 Naves-Díaz M et al. Kidney Int 2008; 74: 1070-1078 10 Tentori F et al. Kidney Int 2006; 70: 1858-1865 11 Teng M et al. N Eng J Med 2003; 349: 446-456 12 Fachinformation Zemplar Weichkapseln. Im Internet: http://www.hyperpara.de/pdf/Zemplar%20Weichkapseln_Fachinfo_Februar_2011.pdf Stand 24.07.2012 13 Block GA et al. N Engl J Med 2004; 350: 1516-1525 14 KDIGO Guideline for Chronic Kidney Disease -Mineral and Bone Disorder (CKD-MBD). Im Internet: http://www.kdigo.org/clinical_practice_guidelines/kdigo_guideline_for_ckd-mbd.php Stand 24.07.2012 15 Ketteler M et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 19.03.2012; [Epub ahead of print]; 16 Fahrleitner-Pammer A et al. J Bone Miner Res 2008; 23: 1850-1858 17 Kovesdy CP et al. Nephrol Dial Transplant 2010; 25: 3003-3011 18 Roggeri P et al. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study. J Med Econ 17.06.2012; [Epub ahead of print]
